Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Reproduction

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1542736

Development and externally validated prediction model of individualization of FSH starting dose in the depot GnRH agonist protocol for the early follicular phase

Provisionally accepted
  • 1 First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 2 Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi Province, China

The final, formatted version of the article will be published soon.

    Each controlled ovarian hyperstimulation(COH) protocol has its own unique mechanism and hormone pattern. The depot GnRHa protocol has a deeper down-regulation effect and favourable clinical pregnancy rates. The predictive model of the optimal follicle-stimulating hormone (FSH) starting dose in the early follicular phase depot GnRH agonist (EFDGa) protocol has not been reported. Our study was made to explore predictive indicators for determining the optimal FSH starting dose in patients undergoing ovarian stimulation with the EFDGa protocol in assisted reproductive technology (ART), and to develop and validate a nomogram prediction model for the starting dose of FSH. Methods This retrospective study included 2733 cycles who underwent fresh cycle transplantation at two large teaching hospitals in China from January to December 2022: center 1 (Reproductive Medicine Center of first affiliated Hospital of Zhengzhou University) provided the data for modelling (n = 938) and internal testing (n = 400), and center 2 (Reproductive Medicine Center of Jiangxi Maternal and Child Health Hospital) provided the data for external testing (n = 1109). Patient demographics, including age, anti-Mullerian hormone (AMH) levels, baseline endocrine profile, and body mass index (BMI), along with information on ovulation stimulation, were collected. Univariate and multivariate linear regression models were used to identify factors influencing the FSH starting dose. A nomogram for the ideal FSH starting dose was developed based on these factors and validated internally and externally. Bland and Altman plots and paired t-tests were conducted to verify the concordance between groups. Results Multivariate analysis revealed that patient age, BMI, basal FSH, AMH, and antral follicle count (AFC) were indicators of FSH starting dose. The regression model for predicting FSH starting dose was determined as: Initial FSH dose = 62.957 +1.780*AGE(years) +4.927*BMI (kg/m ² ) +1.417*bFSH (IU/ml) -1.996*AFC -48.174*AMH (ng/ml). Bland and Altman analysis showed good agreement in the internal validation (bias: 0.583, SD of bias: 33.07IU, 95%LOA: -69.7 to 68.5IU b).

    Keywords: the early follicular phase depot GnRH agonist (EFDGa) protocol, ovarian responsiveness, ideal FSH starting dose, nonogram model, Internal and external validation

    Received: 10 Dec 2024; Accepted: 11 Mar 2025.

    Copyright: © 2025 Fan, Ye, Du, Tian and Kong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Huijuan Kong, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more